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Background/introduction
Among applications of MRgFUS such as uterine fibroid,
breast cancer (BC), metastatice bone tumor, prostate,
and the brain, the breast is prsently the only organ
where complete local control of breast cancer is aimed.
Immediately after completion of excision study (BC003,
2002-2003), one-arm prospective follow-up study to
evaluate MRgFUS followed by adjunct radiation therapy
(BC004) has been running wiht no local and systemic
recurrences among 67 cases at Breastopia Namba Hospital
in Japan. We report completion of excision study (BC006),
the goal of which is, similar to BC003, prospective, non-
randomized, single-arm, multiinternational study, and is to
develop data to evaluate the safety and effectiveness of the
Exablate 2000™ (InSightec, Israel) in the ablation of breast
cancer by histopathological evaluation of MRI-guidance
and the effect of FUS.
A prospective randomized 2-arm study of MRgFUS +
radiation therapy (RT) and breast conserving surgery + RT
will start September, 2014.
Methods
Total of 5 eligible patients agreed to join this study after
IC, May, 2012 - Feb, 2014 at Hokuto Hospital, Obihiro,
Japan, after IRB’s approval. All lesions were diagnosed as
discrete invasive ductal carcinoma wiht a maximal size of
<2cm by ultrasound-guided vacuum biopsy (Vacora™
10 gauge, BARD, USA) and 3T MRI (Signa HDxt, 3T, 8
channel Breast Coil, GE, USA). All the patients underwent
ablation with MRgFUS. The goal of MRgFUS ablation of
breast cancer is to plan and ablate the entire tumor
volume in a treatable and device accessible location (lesion
planned for ablation that is a minimum distance from
unintended structures: dermal under surface, nipple com-
plex and/or ribs shouls be 1.0 cm as defined by procedure
day MR contrast-enhanced imaging, and with margins of
5-10mm by MRgFUS. MR imaging with and without MR
contrast was performed at 10-21 days post ablation in
order to assess the effectiveness of MRI in identifying resi-
dual disease. Pathological analyses will be performed on all
excised samples to assess the endpoints of this study.
Results and conclusions
Median age was 64 ± 13 (51 - 81). All were invasive ductal
carcinoma and luminal A. MRgFUS was all tolerated with
a minimum of adverse effects. On pathological examina-
tion, Median necrosis of the targeted breast tumors was
97.5% ± 2.5(95 - 100%) of tumor volume. The Median %
area of carcinoma within the treatment field was 98 ± 2%
(96% - 100%). Retrospective analysis in two patients with
residual tumor showed treatment was not delivered to the
full recommended area, reaffirming the need for precise
localization and the value of contrast-enhanced images for
treatment planning. Adverse effect were mild except one
patient who complained of moderately uncomfortable feel-
ing in the ablated area of the breast in one patient only
during the treatment.
MRgFUS of early breast cancer was suggested to be
effective and safe treatment.
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